Work

A phase II multicenter study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors (E-VIRTUE).

Year: 2024

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2024.42.16_suppl.tps4628

Authors: Elias Chandran, Nicholas I. Simon, Daniel da Motta Girardi, Lisa Ley, Tzu-fang Wang, Andre Rashad Kydd, Saad Omar Atiq, Salah Boudjadi, Ian Stukes, Elizabeth Smith, Dilara Akbulut, Scot Anthony Niglio, Sandeep Gurram, Marijo Bilusic, Seth M. Steinberg, Andrea B Apolo

Institutions: National Cancer Institute, Center for Cancer Research, National Institutes of Health, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, University of Miami Health System, Sylvester Comprehensive Cancer Center

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4399394232

Cites:

Cited by: 1

Related to: 10